Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical
Overall survival: Median length of · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
- HR 0.65 [0.45, 0.94]1 study · 335 participantsModerate